MedKoo product information:

 Prednimustine

Prednimustine is a drug used in chemotherapy. It is the ester formed from two other drugs, prednisolone and chlorambucil.

According to http://www.answers.com/topic/prednimustine, Prednimustine acts by killing quickly growing cells. Since cancerous cells are generally growing faster than normal cells, drugs that kill quickly growing cells generally affect tumors more than normal cells. However, some normal cells, such as white blood cells and platelets, also grow quickly and can be severely affected by antineoplastic drugs. Antitumor therapies create a situation in which the drug is racing to kill the tumor before it causes irreparable damage to normal tissues. The ideal situation is one in which the growth of the tumor is severely affected, but the growth of normal cells is unaffected. However, not every situation is ideal. Some patients taking antitumor drugs may have to discontinue treatment due to the severity of the drug's side effects.

Prednimustine probably kills rapidly growing cells by modifying cell's DNA with a chemical structure called an alkyl group. Thus, it is included in the group of alkylating agents. Prednimustine is a combination of two drugs joined together: chlorambucil (an alkylating agent) and methylprednisolone (a steroid). Prednimustine is an investigational drug in the United States. This means that the FDA has not approved this drug for marketing in the U.S., as of mid-2010.   

  1: Yamaguchi M. [Treatment of localized nasal NK/T-cell lymphoma]. Rinsho Ketsueki. 2008 Aug;49(8):553-8. Review. Japanese. PubMed PMID: 18800601.

2: Cho JH, Kim HS, Ko YH, Park CS. Epstein-Barr virus infected natural killer cell lymphoma in a patient with hypersensitivity to mosquito bite. J Infect. 2006 Jun;52(6):e173-6. Epub 2005 Oct 24. PubMed PMID: 16246422.

3: Schellong G, Dörffel W, Claviez A, Körholz D, Mann G, Scheel-Walter HG, Bökkerink JP, Riepenhausen M, Lüders H, Pötter R, Rühl U; DAL/GPOH. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol. 2005 Sep 1;23(25):6181-9. PubMed PMID: 16135485.

4: Brosteanu O, Hasenclever D, Loeffler M, Diehl V; German Hodgkin's Lymphoma Study Group. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease. Ann Hematol. 2004 Mar;83(3):176-82. Epub 2003 Dec 12. PubMed PMID: 15064867.

5: Sieber M, Tesch H, Pfistner B, Rueffer U, Paulus U, Munker R, Hermann R, Doelken G, Koch P, Oertel J, Roller S, Worst P, Bischof H, Glunz A, Greil R, von Kalle K, Schalk KP, Hasenclever D, Brosteanu O, Duehmke E, Georgii A, Engert A, Loeffler M, Diehl V, Mueller RP, Willich N, Fischer R, Hansmann ML, Stein H, Schober T, Koch B; German Hodgkin's Lymphoma Study Group. Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Ann Oncol. 2004 Feb;15(2):276-82. PubMed PMID: 14760122.

6: Oborotova NA, Smirnova ZS, Polozkova ZS, Baryshnikov AIu. [Pharmacological aspects in the development of liposomal medicinal preparations for the internal injection of hydrophobic cytostatics]. Vestn Ross Akad Med Nauk. 2002;(1):42-5. Review. Russian. PubMed PMID: 11882971.

7: Peters-Engl C, Medl M, Denison U, Sevelda P, Leodolter S, Petru E. Does long-term application of granulocyte colony-stimulating factor adversely influence overall survival in patients with ovarian cancer? A clinical study. Anticancer Res. 2001 Sep-Oct;21(5):3701-6. PubMed PMID: 11848547.

8: Rodon P, Linassier C, Gauvain JB, Benboubker L, Goupille P, Maigre M, Luthier F, Dugay J, Lucas V, Colombat P. Multiple myeloma in elderly patients: presenting features and outcome. Eur J Haematol. 2001 Jan;66(1):11-7. Review. PubMed PMID: 11168502.

9: Tirelli U, Carbone A, Monfardini S, Zagonel V. A 20-year experience on malignant lymphomas in patients aged 70 and older at a single institute. Crit Rev Oncol Hematol. 2001 Feb;37(2):153-8. Review. PubMed PMID: 11166589.

10: Filipits M, Jaeger U, Simonitsch I, Chizzali-Bonfadin C, Heinzl H, Pirker R. Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas. Clin Cancer Res. 2000 Sep;6(9):3417-23. PubMed PMID: 10999723.

11: Morra E, Gargantini L, Nosari A, Barbarano L, Pungolino E, Santoleri L, Bernuzzi P. Treatment of patients with high-grade non-Hodgkin's lymphoma aged over 70 years with an all-oral regimen combining idarubicin, etoposide and alkylators. Crit Rev Oncol Hematol. 2000 Aug;35(2):95-100. PubMed PMID: 10936466.

12: Pickel H, Lahousen M, Petru E, Stettner H, Hackl A, Kapp K, Winter R. Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer. Gynecol Oncol. 1999 Feb;72(2):215-9. PubMed PMID: 10021304.

13: Yau JC, Germond C, Gluck S, Cripps C, Verma S, Burns BF, Koski TM, Lister DC, Goss GD. Mitoxantrone, prednimustine, and vincristine for elderly patients with aggressive non-Hodgkin's lymphoma. Am J Hematol. 1998 Oct;59(2):156-60. PubMed PMID: 9766801.

14: Gómez H, Colomer R. [Treatment of lymphoma in the aged]. Med Clin (Barc). 1998 May 2;110(15):574-5. Review. Spanish. PubMed PMID: 9650201.

15: Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol. 1998;124(3-4):207-14. Review. PubMed PMID: 9619748.

16: Ezpeleta Echávarri D, Muñoz-Blanco JL, Diaz-Otero F, Giménez Roldán S. [Myoclonus induced by prednimustine]. Neurologia. 1998 Mar;13(3):154-5. Review. Spanish. PubMed PMID: 9608225.

17: Hiddemann W, Unterhalt M, Herrmann R, Wöltjen HH, Kreuser ED, Trümper L, Reuss-Borst M, Terhardt-Kasten E, Busch M, Neubauer A, Kaiser U, Hanrath RD, Middeke H, Helm G, Freund M, Stein H, Tiemann M, Parwaresch R. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol. 1998 May;16(5):1922-30. PubMed PMID: 9586911.

18: Rodríguez JN, Fernández-Jurado A, Martino ML, Prados D. Waldenström's macroglobulinemia complicated with acute myeloid leukemia. Report of a case and review of the literature. Haematologica. 1998 Jan;83(1):91-2. Review. PubMed PMID: 9542328.

19: Iglesias L, Moreno JA, Torrija E, Murillo E, Codes M, Dugue A, Garcia E, Virizuela JA. UFT in combination as adjuvant therapy for breast cancer. Grupo Oncologico de Sevilla Seville, Spain. Oncology (Williston Park). 1997 Sep;11(9 Suppl 10):74-81. PubMed PMID: 9348574.

20: Tirelli U, Errante D, Van Glabbeke M, Teodorovic I, Kluin-Nelemans JC, Thomas J, Bron D, Rosti G, Somers R, Zagonel V, Noordijk EM. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol. 1998 Jan;16(1):27-34. PubMed PMID: 9440719.

21: Heinz R, Hopfinger G, Tüchler H. Outcome of patients with low-grade B cell non-Hodgkin lymphoma and initial bone marrow involvement: data of a single institution. Leukemia. 1997 Apr;11 Suppl 2:S52-4. PubMed PMID: 9178841.

22: Brice P, Bastion Y, Lepage E, Brousse N, Haïoun C, Moreau P, Straetmans N, Tilly H, Tabah I, Solal-Céligny P. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997 Mar;15(3):1110-7. PubMed PMID: 9060552.

23: Barnadas A, Mendiola C, Casado A, Villar A, Jimeno J, Clerigue M, Rosell R, Diaz-Rubio E, Cortés-Funes H, García de Paredes M. Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study. Eur J Cancer. 1997 Feb;33(2):312-5. PubMed PMID: 9135508.

24: Monnerat C, Gander M, Leyvraz S. A rare case of prednimustine-induced myoclonus. J Natl Cancer Inst. 1997 Jan 15;89(2):173-4. PubMed PMID: 8998190.

25: Maurizi Enrici R, Anselmo AP, Osti MF, Santoro M, Tombolini V, Mandelli F, Biagini C. Analysis of the risk of solid tumor following Hodgkin's disease. Haematologica. 1997 Jan-Feb;82(1):57-63. PubMed PMID: 9107084.

26: Braess J, Kern W, Unterhalt M, Kaufmann CC, Ramsauer B, Schüssler M, Kaeser-Fröhlich A, Hiddemann W, Schleyer E. Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone. Ann Hematol. 1996 Oct;73(4):201-4. PubMed PMID: 8890711.

27: Tirelli U, Errante D, Spina M, Gastaldi R, Nigra E, Nosari AM, Magnani G, Vaccher E. Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients. Cancer. 1996 May 15;77(10):2127-31. PubMed PMID: 8640681.

28: Unterhalt M, Herrmann R, Tiemann M, Parwaresch R, Stein H, Trümper L, Nahler M, Reuss-Borst M, Tirier C, Neubauer A, Freund M, Kreuser ED, Dietzfelbinger H, Bodenstein H, Engert A, Stauder R, Eimermacher H, Landys K, Hiddemann W. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. Leukemia. 1996 May;10(5):836-43. PubMed PMID: 8656680.

29: Hiddemann W. Non-Hodgkin's lymphomas--current status of therapy and future perspectives. Eur J Cancer. 1995 Dec;31A(13-14):2141-5. Review. PubMed PMID: 8652232.

30: Dreger P, Klöss M, Petersen B, Haferlach T, Löffler H, Loeffler M, Schmitz N. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood. 1995 Nov 15;86(10):3970-8. PubMed PMID: 7579368.

31: Hiura M, Murakami J, Shigemasa K, Fujioka T, Yokoyama T, Nogawa T, Chiba T, Shimokawa T. [Study on peripheral blood stem cells mobilized by different chemotherapies with granulocyte-colony stimulating factor in ovarian cancer]. Nippon Sanka Fujinka Gakkai Zasshi. 1995 Mar;47(3):257-63. Japanese. PubMed PMID: 7535329.

32: Zinzani PL, Barbieri E, Bendandi M, Perini F, Gherlinzoni F, Neri S, Ammendolia I, Salvucci M, Babini L, Fiacchini M, et al. CEP regimen (CCNU, etoposide, prednimustine) for relapsed/refractory Hodgkin's disease. Tumori. 1994 Dec 31;80(6):438-42. PubMed PMID: 7900233.

33: Zinzani PL, Barbieri E, Visani G, Gherlinzoni F, Perini F, Neri S, Bendandi M, Ammendolia I, Salvucci M, Babini L, et al. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease. Haematologica. 1994 Nov-Dec;79(6):508-12. PubMed PMID: 7534744.

34: Travis LB, Curtis RE, Stovall M, Holowaty EJ, van Leeuwen FE, Glimelius B, Lynch CF, Hagenbeek A, Li CY, Banks PM, et al. Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst. 1994 Oct 5;86(19):1450-7. PubMed PMID: 8089863.

35: Roncadin M, Arcicasa M, Zagonel V, Bortolus R, Valeri P, Pinto A, De Paoli A, Franchin G, Carbone A, Trovò MG. Total body irradiation and prednimustine in chronic lymphocytic leukemia and low grade non-Hodgkin's lymphomas. A 9-year experience at a single institution. Cancer. 1994 Aug 1;74(3):978-84. PubMed PMID: 8039128.

36: Damianov C, Terziev T, Koleva P, Chuchkova M. Combined immunochemotherapy (CEP, M-VEP + BCG) in the treatment of invasive bladder tumors. Anticancer Drugs. 1994 Jun;5(3):298-304. PubMed PMID: 7919454.

37: Illés A, Bányai A, Szegedi G. [Treatment of advanced stage Hodgkin disease with CCNU, etoposide and prednimustine (CEP)]. Orv Hetil. 1994 May 29;135(22):1187-90. Review. Hungarian. PubMed PMID: 8015814.

38: Hiddemann W, Unterhalt M, Koch P, Nahler M, Herrmann R. New aspects in the treatment of advanced low-grade non-Hodgkin's lymphomas: prednimustine/mitoxantrone versus cyclophosphamide/vincristine/prednisone followed by interferon alfa versus observation only--a preliminary update of the German Low-Grade Lymphoma Study Group. Semin Hematol. 1994 Apr;31(2 Suppl 3):32-5. PubMed PMID: 8073307.

39: Tirelli U, Zagonel V, Sorio R, Errante D, Talamini R, Carbone A, Monfardini S. Mitoxantrone in combination with etoposide and prednimustine in patients older than 70 years with unfavorable non-Hodgkin's lymphoma: a prospective study in 52 patients. Semin Hematol. 1994 Apr;31(2 Suppl 3):13-22. PubMed PMID: 8073302.

40: Martin M, Diaz-Rubio E, Casado A, Valverde JJ, Garcia Urra D, López-Martin JA, Rodriguez-Lescure A. Prednimustine-induced myoclonus--a report of three cases. Acta Oncol. 1994;33(1):81-2. PubMed PMID: 8142134.

41: Medl M, Peters-Engel C, Fuchs G, Leodolter S. Triptorelin (D-Trp-6-LHRH) in combination with carboplatin-containing polychemotherapy for advanced ovarian cancer: a pilot study. Anticancer Res. 1993 Nov-Dec;13(6B):2373-6. PubMed PMID: 8135470.

42: De Lena M, Ditonno P, Lorusso V, Timurian A, Pellecchia A, Brandi M, Berardi F, Marzullo F. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy). Haematologica. 1993 Jul-Aug;78(4):230-5. PubMed PMID: 7507457.

43: Alberto P. Phase II study of an oral combination of doxifluridine, prednimustine and idarubicin (FUPRIDA) for first line treatment of advanced breast cancer. Ann Oncol. 1993 May;4(5):423-5. PubMed PMID: 8353076.

44: Yosef H, Slater A, Keen CW, Bunting JS, Hope-Stone H, Parmar H, Roberts JT, Termander B, Nilsson B. Prednimustine (Sterecyt) versus cyclophosphamide both in combination with methotrexate and 5-fluorouracil in the treatment of advanced breast cancer. Eur J Cancer. 1993;29A(8):1100-5. PubMed PMID: 8518020.

45: Hatschek T, Baldetorp L, Carstensen J, Håkansson L, Möller T, Nilsson B, Termander B. Continuous versus intermittent prednimustine treatment of non-Hodgkin's lymphoma. Med Oncol Tumor Pharmacother. 1993;10(4):159-66. PubMed PMID: 8164452.

46: Lindh J, Jonsson H, Lenner P, Roos G. 'Aggressive' low grade lymphocytic lymphomas can be identified by flow cytometric S-phase determinations. Hematol Oncol. 1992 May-Aug;10(3-4):171-9. PubMed PMID: 1398513.

47: Tirelli U, Zagonel V, Errante D, Serraino D, Talamini R, De Cicco M, Carbone A, Monfardini S. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma. J Clin Oncol. 1992 Feb;10(2):228-36. PubMed PMID: 1732423.

48: Freund M, Wunsch-Zeddies S, Schäfers M, Wysk J, Seidel I, Hiddemann W, Hanauske AR, Link H, Schmoll HJ, Poliwoda H. Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL). Ann Hematol. 1992 Feb;64(2):83-7. PubMed PMID: 1554799.

49: Lindgren S, Danielsson A, Olsson R, Prytz H, Eriksson S. Prednimustin treatment in primary biliary cirrhosis: a preliminary study. J Intern Med. 1992 Feb;231(2):139-41. PubMed PMID: 1541936.

50: Lundberg B. Assembly of prednimustine low-density-lipoprotein complexes and their cytotoxic activity in tissue culture. Cancer Chemother Pharmacol. 1992;29(3):241-7. PubMed PMID: 1733558.

51: Musch E, Malek M, Peter-Katalinic J, Egge H, Rink H, Lathan B, Riedel E. Cellular kinetics of prednimustine versus chlorambucil plus prednisolone in vitro. Cancer Chemother Pharmacol. 1992;29(4):297-304. PubMed PMID: 1537076.

52: Petru E, Pickel H, Heydarfadai M, Lahousen M. Remission induction with carboplatin-epirubicin-prednimustine followed by consolidation radiotherapy in advanced ovarian cancer. Int J Clin Pharmacol Res. 1992;12(4):205-7. PubMed PMID: 1297644.

53: Smyth JF, Beattie GJ, Stewart ME, Cowie VJ, Smart GE, Livingstone JR, Leonard RC. Cisplatinum and prednimustine, an active regimen for advanced epithelial ovarian cancer. Ann Oncol. 1991 Nov-Dec;2(10):755-8. PubMed PMID: 1801882.

54: Andreopoulos D, Klose KC, Glöckner WM. [Thymus hyperplasia after chemotherapy in a case of Hodgkin's disease]. Rofo. 1991 Oct;155(4):375-6. German. PubMed PMID: 1718486.

55: Lazo JS, Basu A. Metallothionein expression and transient resistance to electrophilic antineoplastic drugs. Semin Cancer Biol. 1991 Aug;2(4):267-71. Review. PubMed PMID: 1912530.

56: Pickel H, Petru E, Lahousen M, Stettner H, Heydarfadai M, Arian-Schad K, Hackl A. Consolidation radiotherapy following carboplatin-based chemotherapy in radically operated advanced ovarian cancer. A pilot study. Am J Clin Oncol. 1991 Jun;14(3):184-7. PubMed PMID: 2031503.

57: Fermé C, Brice P, Bourstyn E, D'Agay MF, Lepage E, Miclea JM, Fermand JP, Extra JM, Frija J, Colin P, et al. Surgical restaging of advanced Hodgkin's disease after first line chemotherapy. Eur J Haematol. 1991 May;46(5):306-11. PubMed PMID: 1710575.

58: Samonigg H, Stöger H, Kasparek AK, Schmid M, Dusleag J, Pfeiffer K, Smola M, Steindorfer P, Lechner P. Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. Cancer Chemother Pharmacol. 1991;27(6):477-80. PubMed PMID: 2013118.

59: Berger MR. Strategies of reducing the carcinogenic risk of cytostatic agents on the basis of bioassay evaluation. Neoplasma. 1991;38(4):369-78. PubMed PMID: 1922569.

60: O'Brien ME, Eccles DM, Allen SG, Knight G, Rodger A, Chetty U, Smyth JF, Leonard RC. Mitozantrone and prednimustine in the treatment of advanced breast cancer--a toxic regimen with low activity. Cancer Chemother Pharmacol. 1991;28(5):402-4. PubMed PMID: 1914086.

61: Loos U, Musch E, Malek M, Riedel E. Comparative pharmacokinetics of chlorambucil and prednimustine after oral administration. Oncology. 1991;48(4):334-42. PubMed PMID: 1891177.

62: Fiorentino MV. Lymphomas in the elderly. Leukemia. 1991;5 Suppl 1:79-85. Review. PubMed PMID: 1890872.

63: Carella A, Carlier P, Congiu A, Occhini D, Meloni G, Anselmo AP, Mandelli F, Mazza P, Tura S, Mangoni L, et al. Nine years' experience with ABMT in 128 patients with Hodgkin's disease: an Italian study group report. Leukemia. 1991;5 Suppl 1:68-71. PubMed PMID: 1890870.

64: Roncadin M, Arcicasa M, Bortolus R, Trovó MG, Carbone A, Tirelli U, De Paoli A, Franchin G, Grigoletto E. Feasibility of total body irradiation in chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphomas. Cancer Invest. 1991;9(4):403-7. PubMed PMID: 1884246.

65: Bastholt L, Johansson CJ, Pfeiffer P, Svensson L, Johansson SA, Gunnarsson PO, Mouridsen H. A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients. Cancer Chemother Pharmacol. 1991;28(3):205-10. PubMed PMID: 1855277.

66: Hiddemann W, Unterhalt M, Koch P, Nahler M, Herrmann R, van de Loo J. alpha Interferon maintenance therapy in patients with low-grade non-Hodgkin's lymphomas after cytoreductive chemotherapy with prednimustine and mitoxantrone. Eur J Cancer. 1991;27 Suppl 4:S37-9. PubMed PMID: 1799474.

67: Szántó I, Fleischmann T, Eckhardt S. Treatment of resistant Hodgkin's disease with CCNU, etoposide and prednimustine (CEP). Oncology. 1991;48(6):456-8. PubMed PMID: 1749581.

68: Hiddemann W, Unterhalt M, Koch P, Nahler M, van de Loo J. Treatment of low-grade non-Hodgkin's lymphoma by cytoreductive chemotherapy with prednimustine/mitoxantrone followed by interferon alpha-2b maintenance: results of a clinical phase II study. Semin Oncol. 1990 Dec;17(6 Suppl 10):20-3. PubMed PMID: 2259919.

69: Petru E, Pickel H, Lahousen M, Boike G, Heydarfadai M. Combination chemotherapy in radically operated advanced ovarian cancer. Cancer Treat Rev. 1990 Sep;17(2-3):329-34. PubMed PMID: 2272048.

70: Andersson M, Philip P, Pedersen-Bjergaard J. High risk of therapy-related leukemia and preleukemia after therapy with prednimustine, methotrexate, 5-fluorouracil, mitoxantrone, and tamoxifen for advanced breast cancer. Cancer. 1990 Jun 1;65(11):2460-4. PubMed PMID: 2337861.

71: Solal-Celigny P, Tertian G, Herrera A, Brousse N, Peuchmaur M. [Treatment of aggressive non-Hodgkin's lymphoma in aged patients with a combination of methyl-GAG, etoposide and prednimustine]. Bull Cancer. 1990;77(5):449-52. French. PubMed PMID: 2400814.

72: Weiss C, Ho AD, Hiller E, Thiel E, Schlag R, Lipp T, Herrmann R, Musch E, Termander B, Hunstein W. Prognostic significance of glucocorticoid receptor determination in patients with chronic lymphocytic leukemia and immunocytoma--lack of a positive correlation between receptor levels and clinical responsiveness. Leuk Res. 1990;14(4):327-32. PubMed PMID: 2332986.

73: Greig NH, Genka S, Daly EM, Sweeney DJ, Rapoport SI. Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration. Cancer Chemother Pharmacol. 1990;25(5):311-9. PubMed PMID: 2306790.

74: Prednimustine. IARC Monogr Eval Carcinog Risks Hum. 1990;50:115-22. Review. PubMed PMID: 2292795.

75: Zagonel V, Tirelli U, Carbone A, Errante D, Morassot S, Sorio R, Monfardini S. Combination chemotherapy specifically devised for elderly patients with unfavorable non-Hodgkin's lymphoma. Cancer Invest. 1990;8(6):577-82. PubMed PMID: 2292050.

76: Kimura T, Schön A, Wadsö I. Prediction of the cytotoxic effects of some antineoplastic drugs on cultured T-lymphoma cells by microcalorimetry. Cytobios. 1990;63(252):7-13. PubMed PMID: 2257759.

77: von Hirschhausen R, Steinke B, Saal JG. Treatment of advanced Hodgkin's disease with lomustine, etoposide, and prednimustine. Eur J Cancer. 1990;26(6):768-9. PubMed PMID: 2144172.

78: Viviani S, Santoro A, Negretti E, Bonfante V, Valagussa P, Bonadonna G. Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission. Ann Oncol. 1990;1(2):123-7. PubMed PMID: 1706614.

79: Hausmaninger H, Lehnert M, Steger G, Sevelda P, Michlmayr G, Hehenwarter W, Fridrik M, Samonigg H, Schiller L, Manfreda D, et al. Vindesine-epirubicin versus vindesine-mitoxantrone in metastatic breast cancer. Onkologie. 1989 Oct;12(5):225-9. PubMed PMID: 2685688.

80: Mahe M, Raffi F, Grolleau JY, Baudot S. [Acute monoblastic leukemia in non-Hodgkin's malignant lymphoma treated with prednimustine]. Therapie. 1989 Sep-Oct;44(5):378-9. French. PubMed PMID: 2814920.

81: Kaufmann M, Schmid H, Raeth U. Mitoxantrone and prednimustine combination chemotherapy in breast cancer. J Chemother. 1989 Jul;1(4 Suppl):1191-3. PubMed PMID: 16312829.

82: Musch E, Loos U, Alléra A, Hügl E, Pütz I, Malek M. Pharmacokinetic and cell-biological investigation of prednimustine compared to its components chlorambucil and prednisolone. J Chemother. 1989 Jul;1(4 Suppl):1127-9. PubMed PMID: 16312803.

83: Oppitz MM, Musch E, Malek M, Rüb HP, von Unruh GE, Loos U, Mühlenbruch B. Studies on the pharmacokinetics of chlorambucil and prednimustine in patients using a new high-performance liquid chromatographic assay. Cancer Chemother Pharmacol. 1989;23(4):208-12. PubMed PMID: 2924378.

84: Pickel H. [Carboplatin/epirubicin/prednimustine (Sterecyt) as an adjuvant chemotherapy combination in ovarian cancer treated by radical surgery]. Gynakol Rundsch. 1989;29 Suppl 2:357-8. German. PubMed PMID: 2693256.

85: Szántó I, Fleischmann T, Eckhardt S. Prednimustine treatment in malignant lymphomas. Oncology. 1989;46(4):205-7. PubMed PMID: 2662086.

86: Leonard RC, Smart GE, Livingstone JR, Cornbleet MA, Kerr GR, Fletcher S, Webb JN, Smyth JF. Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma. Cancer Chemother Pharmacol. 1989;23(2):105-10. PubMed PMID: 2491962.

87: Doberauer C, Ohl S. Advanced mycosis fungoides: chemotherapy with etoposide, methotrexate, bleomycin, and prednimustine. Acta Derm Venereol. 1989;69(6):538-40. PubMed PMID: 2481928.

88: Carella AM, Congiu AM, Gaozza E, Mazza P, Ricci P, Visani G, Meloni G, Cimino G, Mangoni L, Coser P, et al. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report. J Clin Oncol. 1988 Sep;6(9):1411-6. PubMed PMID: 2458439.

89: Landys KE. Mitoxantrone in combination with prednimustine in treatment of unfavorable non-Hodgkin lymphoma. Invest New Drugs. 1988 Jun;6(2):105-13. PubMed PMID: 3170130.

90: Cervantes F, Reverter JC, Bladé J, Montserrat E, Rozman C. [Treatment with CEP (CCNU, VP-16 and prednimustine) in Hodgkin's disease resistant to CVPP and ABVD. Results in 21 patients]. Sangre (Barc). 1988 Jun;33(3):184-7. Spanish. PubMed PMID: 2459787.

91: Marini G, Simoncini E, Marpicati P, Montini E, Ferrari V, Arcangeli G, Zaniboni A. Premarin priming before prednimustine, high-dose folinic acid and 5-fluorouracil as salvage chemotherapy for advanced breast cancer. Chemioterapia. 1988 Apr;7(2):130-2. PubMed PMID: 2840216.

92: Ohsawa N. [Clinical experiences in tumor-oriented anti-cancer drugs]. Nippon Naika Gakkai Zasshi. 1988 Mar;77(3):313-7. Japanese. PubMed PMID: 2841390.

93: Andersson M, Mouridsen HT. Prednimustine, methotrexate, 5-fluorouracil, mitoxantrone and tamoxifen for advanced breast cancer in postmenopausal women. A phase II trial. Acta Oncol. 1988;27(3):235-9. PubMed PMID: 3415852.

94: Pedersen L, Løber J, Dalmark M, Mouridsen HT. Prednimustine in advanced malignant melanoma: a phase II study. Cancer Treat Rep. 1987 Dec;71(12):1315-6. PubMed PMID: 3690549.

95: Kosmidis PA, Fountzilas G, Athanassiou A, Karabelis A, Mylonakis N, Tsavaris N, Karvounis N, Bacojiannis C. Combination chemotherapy with prednimustine, adriamycin, vincristine (VAP) in advanced breast cancer. A phase II study. Chemioterapia. 1987 Dec;6(6):393-5. PubMed PMID: 3435921.

96: Lenk H, Müller U, Tanneberger S. Mitoxantrone: mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity. Anticancer Res. 1987 Nov-Dec;7(6):1257-64. Review. PubMed PMID: 3327453.

97: Rankin EM, Harvey C, Knight RK, Rubens RD. Phase II trial of prednimustine as first-line chemotherapy in patients with advanced breast cancer. Cancer Treat Rep. 1987 Nov;71(11):1107-8. PubMed PMID: 3119205.

98: Tirelli U, Carbone A, Zagonel V, Veronesi A, Canetta R. Non-Hodgkin's lymphomas in the elderly: prospective studies with specifically devised chemotherapy regimens in 66 patients. Eur J Cancer Clin Oncol. 1987 May;23(5):535-40. PubMed PMID: 3653177.

99: Gandara DR, George CB, Ries CA, Koretz MM, Lewis JP. Treatment of refractory chronic lymphocytic leukemia with prednimustine: a phase II study using strict response criteria. Cancer Chemother Pharmacol. 1987;19(2):165-8. PubMed PMID: 3568275.

100: Ito Y, Ogawa M, Horikoshi N, Inoue K, Mukaiyama T, Nakamura T, Ueno K, Imajou K, Miyaoka K, Ozeki H, et al. [Phase II study of prednimustine in follicular lymphoma and chronic lymphocytic leukemia]. Gan To Kagaku Ryoho. 1987 Jan;14(1):173-8. Japanese. PubMed PMID: 3541792.

101: Endresen L, Rugstad HE. Protective function of metallothionein against certain anticancer agents. Experientia Suppl. 1987;52:595-602. PubMed PMID: 2959550.

102: Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med. 1986 Jun;104(6):739-46. PubMed PMID: 2422994.

103: Cervantes F, Reverter JC, Montserrat E, Rozman C. Treatment of advanced resistant Hodgkin's disease with lomustine, etoposide, and prednimustine. Cancer Treat Rep. 1986 May;70(5):665-7. PubMed PMID: 3708614.

104: Tirelli U, Sorio R, Magri MD, Zagonel V, Vaccher E, Carbone A, Trovò M, Grigoletto E. Prednimustine in elderly patients with multiple myeloma: a phase II study. Cancer Treat Rep. 1986 Apr;70(4):537-8. PubMed PMID: 3698051.

105: Berger MR, Habs M, Schmähl D. Long-term toxicology effects of prednimustine in comparison with chlorambucil, prednisolone, and chlorambucil plus prednisolone in Sprague-Dawley rats. Semin Oncol. 1986 Mar;13(1 Suppl 1):8-13. PubMed PMID: 3952521.

106: Mouridsen HT, Andersson M, Pedersen L. Combined cytotoxic and endocrine treatment of postmenopausal patients with advanced breast cancer: preliminary results of a phase II study of the combination of prednimustine, novantrone, methotrexate, 5-fluorouracil, and tamoxifen. Semin Oncol. 1986 Mar;13(1 Suppl 1):39-41. PubMed PMID: 3952520.

107: Hartley-Asp B. The antitumor effect of prednimustine in vitro and in vivo. Semin Oncol. 1986 Mar;13(1 Suppl 1):3-7. PubMed PMID: 3952519.

108: Cavallin-Ståhl E, Möller TR. Prednimustine v cyclophosphamide-vincristine-prednisolone in the treatment of non-Hodgkin's lymphoma with favorable histopathology: results of a national cancer care program in Sweden. Semin Oncol. 1986 Mar;13(1 Suppl 1):19-22. PubMed PMID: 3952518.

109: Gandara DR, Wold HG, Redmond J, Kohler M, Reynolds R, Wong P, Forsythe J, Fisher K, Lewis B. Prednimustine in refractory non-Hodgkin's lymphoma: a phase II study of the Northern California Oncology Group. Semin Oncol. 1986 Mar;13(1 Suppl 1):14-8. PubMed PMID: 3952517.

110: Prednimustine. Semin Oncol. 1986 Mar;13(1 Suppl 1):1-44. PubMed PMID: 3952516.

111: Schein PS, Cavalli F. Prednimustine: the rationale for clinical development. Semin Oncol. 1986 Mar;13(1 Suppl 1):1-2. PubMed PMID: 3952515.

112: Lehnert M, Biffl G, Wascher H, Jordis-Lohausen K, Wählby S. A preliminary analysis of combination therapy with vincristine, adriamycin, and prednimustine (VAP) in advanced breast cancer: a phase II study. Semin Oncol. 1986 Mar;13(1 Suppl 1):32-4. PubMed PMID: 3754064.

113: Allegra JC. A randomized comparative study of prednimustine and doxorubicin in patients with metastatic breast cancer. Semin Oncol. 1986 Mar;13(1 Suppl 1):42-4. PubMed PMID: 3513319.

114: Mouridsen HT. Prednimustine in advanced breast cancer: a review. Semin Oncol. 1986 Mar;13(1 Suppl 1):27-31. Review. PubMed PMID: 3513318.

115: Aapro MS, Forni M, Krauer F, Alberto P, Wählby S. Preliminary analysis of combined treatment with prednimustine and 4'epidoxorubicin in advanced breast cancer. Semin Oncol. 1986 Mar;13(1 Suppl 1):35-8. PubMed PMID: 3456646.

116: Santoro A, Viviani S, Valagussa P, Bonfante V, Bonadonna G. CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease. Semin Oncol. 1986 Mar;13(1 Suppl 1):23-6. PubMed PMID: 2420012.

117: Hartley-Asp B, Gunnarsson PO, Liljekvist J. Cytotoxicity and metabolism of prednimustine, chlorambucil and prednisolone in a Chinese hamster cell line. Cancer Chemother Pharmacol. 1986;16(2):85-90. PubMed PMID: 3948307.

118: Zaffaroni N, Silvestrini R, Sanfilippo O, Daidone MG, Gasparini G. In vitro activity of alkylating agents on human tumors as measured by a short-term antimetabolic assay. Tumori. 1985 Dec 31;71(6):555-61. PubMed PMID: 4082288.

119: Bonadonna G, Viviani S, Valagussa P, Bonfante V, Santoro A. Third-line salvage chemotherapy in Hodgkin's disease. Semin Oncol. 1985 Mar;12(1 Suppl 2):23-5. PubMed PMID: 2579440.

120: Berger MR, Habs M, Schmähl D. Comparative carcinogenic activity of prednimustine, chlorambucil, prednisolone and chlorambucil plus prednisolone in Sprague-Dawley rats. Arch Geschwulstforsch. 1985;55(6):429-42. PubMed PMID: 4083998.

121: Klener P, Háber J. Value of prednimustine in treating non Hodgkin's lymphomas of favourable histological type. Folia Haematol Int Mag Klin Morphol Blutforsch. 1985;112(1):103-8. PubMed PMID: 2581855.

122: Endresen L, Schjerven L, Rugstad HE. Tumours from a cell strain with a high content of metallothionein show enhanced resistance against cis-dichlorodiammineplatinum. Acta Pharmacol Toxicol (Copenh). 1984 Sep;55(3):183-7. PubMed PMID: 6542297.

123: Thigpen JT, Vance RB, Balducci L, Khansur T. New drugs and experimental approaches in ovarian cancer treatment. Semin Oncol. 1984 Sep;11(3):314-26. Review. PubMed PMID: 6435251.

124: Gunnarsson PO, Johansson SA, Svensson L. Cholesterol ester formation by transesterification of chlorambucil: a novel pathway in drug metabolism. Xenobiotica. 1984 Jul;14(7):569-74. PubMed PMID: 6506771.

125: Andersen J, Christensen L, Kongsholm H. Phase II trial of prednimustine in glioblastoma multiforme. Cancer Treat Rep. 1984 May;68(5):795-7. PubMed PMID: 6327038.

126: deKernion JB, Lindner A. Chemotherapy of hormonally unresponsive prostatic carcinoma. Urol Clin North Am. 1984 May;11(2):319-26. Review. PubMed PMID: 6233779.

127: Endresen L. Comparison of the cytotoxic effect of prednimustine in cultured cells with high or low levels of metallothionein. Acta Pharmacol Toxicol (Copenh). 1984 Jan;54(1):49-57. PubMed PMID: 6702467.

128: Newell DR, Calvert AH, Harrap KR, McElwain TJ. The clinical pharmacology of chlorambucil and prednimustine. Br J Clin Pharmacol. 1983 Dec;16(6):762-3. PubMed PMID: 6661370; PubMed Central PMCID: PMC1428359.

129: Plym Forshell G, Gunnarsson PO, Liljekvist J. On the clinical pharmacology of prednimustine. Br J Clin Pharmacol. 1983 Dec;16(6):760-1. PubMed PMID: 6661369; PubMed Central PMCID: PMC1428354.

130: Løber J, Mouridsen HT, Christiansen IE, Dombernowsky P, Mattsson W, Rørth M. A phase III trial comparing prednimustine (LEO 1031) to chlorambucil plus prednisolone in advanced breast cancer. Cancer. 1983 Nov 1;52(9):1570-6. PubMed PMID: 6352005.

131: Murphy GP, Slack NH, Mittelman A. Experiences with estramustine phosphate (Estracyt, Emcyt) in prostate cancer. Semin Oncol. 1983 Sep;10(3 Suppl 3):34-42. PubMed PMID: 6364365.

132: Ayulo MA, Preisler HD. Prednimustine in acute nonlymphocytic leukemia. Am J Clin Oncol. 1983 Apr;6(2):207-9. PubMed PMID: 6829495.

133: Newell DR, Calvert AH, Harrap KR, McElwain TJ. Studies on the pharmacokinetics of chlorambucil and prednimustine in man. Br J Clin Pharmacol. 1983 Feb;15(2):253-8. PubMed PMID: 6849759; PubMed Central PMCID: PMC1427847.

134: Mouridsen HT, Boesen E. Prednimustine in combination with methotrexate and 5-fluorouracil in advanced breast cancer: a phase I-II study. Breast Cancer Res Treat. 1983;3(1):85-9. PubMed PMID: 6871484.

135: Ehrsson H, Wallin I, Nilsson SO, Johansson B. Pharmacokinetics of chlorambucil in man after administration of the free drug and its prednisolone ester (prednimustine, Leo 1031). Eur J Clin Pharmacol. 1983;24(2):251-3. PubMed PMID: 6840176.

136: Gaver RC, Deeb G, Pittman KA, Issell BF, Mittelman A, Smyth RD. Disposition of orally administered 14C-prednimustine in cancer patients. Cancer Chemother Pharmacol. 1983;11(3):139-43. PubMed PMID: 6640823.

137: Boesen E, Mouridsen HT. Prednimustine in combination with methotrexate and 5-FU (PMF): a pilot study. Cancer Treat Rep. 1982 Dec;66(12):2081-3. PubMed PMID: 7139649.

138: Ideström K, Kimby E, Björkholm M, Mellstedt H, Engstedt L, Gahrton G, Johansson B, Killander D, Robérts KH, Stalfelt AM, Udén AM, Wadman B, Wählby S. Treatment of chronic lymphocytic leukaemia and well-differentiated lymphocytic lymphoma with continuous low- or intermittent high-dose prednimustine versus chlorambucil/prednisolone. Eur J Cancer Clin Oncol. 1982 Nov;18(11):1117-23. PubMed PMID: 6897633.

139: Gaynon PS, Baum ES, Krivit W, Hammond D. Phase II trial of prednimustine in children with recurrent cancer: a Children's Cancer Study Group report. Cancer Treat Rep. 1982 Jul;66(7):1583-4. PubMed PMID: 6284362.

140: Lönnqvist B, Andersson B, Björkholm M, Engstedt L, Gahrton G, Hast R, Holm G, Killander A, Lantz B, Lockner D, Mellstedt H, Palmblad J, Paul C, Peterson C, Simonsson B, Stalfelt AM, Udén AM, Wadman B, Oberg G. Prednimustine and vincristine compared with cytosine arabinoside and thioguanine for treatment of elderly patients with acute nonlymphoblastic leukemia. Cancer Chemother Pharmacol. 1982;9(2):89-92. PubMed PMID: 7172410.

141: Gandara DR, Ries CA, Schiff SA, George CB, Lewis JP, Koretz MM, Carter SK. A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts. Cancer Chemother Pharmacol. 1982;9(1):10-2. PubMed PMID: 7139848.

142: Karakousis CP, Didolkar MS, Ambrus JL, Holyoke ED. Prednimustine in advanced soft tissue sarcomas. Cancer Treat Rep. 1982 Jan;66(1):201-2. PubMed PMID: 7053259.

143: Beckley S, Wajsman LZ, Slack NH, Murphy GP. Chemotherapy in metastatic, hormone refractory prostatic cancer using chlorambucil in combination with prednisolone versus conjugate, prednimustine (Leo 1031). Urology. 1981 May;17(5):446-8. PubMed PMID: 7015669.

144: Sayed A, Hove WV, Vermeulen A. Prednisolone plasma levels after oral administration of Prednimustine. Comparison with levels obtained after administration of an equimolar dose of prednisolone. Oncology. 1981;38(6):351-5. PubMed PMID: 7301281.

145: Newell DR, Shepherd CR, Harrap KR. The pharmacokinetics of prednimustine and chlorambucil in the rat. Cancer Chemother Pharmacol. 1981;6(1):85-91. PubMed PMID: 7273268.

146: Grundsell H, Johnsson JE, Tropé C. [A phase II study of prednimustine in advanced ovarian cancer]. Lakartidningen. 1980 Sep 24;77(39):3394-7. Swedish. PubMed PMID: 6161283.

147: Rutkowski A. [Problems of treatment of prostatic cancer]. Wiad Lek. 1980 Sep 15;33(18):1461-6. Polish. PubMed PMID: 6781145.

148: Mouridsen HT, Kristensen D, Nielsen JH, Dombernowsky P. Phase II trial of prednimustine, L-1031, (NSC-134087) in advanced breast cancer. Cancer. 1980 Jul 15;46(2):253-5. PubMed PMID: 7388770.

149: Schmidt JD. Chemotherapy of hormone-resistant stage D prostatic cancer. J Urol. 1980 Jun;123(6):797-805. PubMed PMID: 7189791.

150: Biörklund A, Håkansson L, Stenstam B, Tropé C, Akerman M. On heterogeneity of non-Hodgkin's lymphomas as regards sensitivity to cytostatic drugs. An in vitro study. Eur J Cancer. 1980 May;16(5):647-54. PubMed PMID: 7389791.

151: Torti FM, Carter SK. The chemotherapy of prostatic adenocarcinoma. Ann Intern Med. 1980 May;92(5):681-9. Review. PubMed PMID: 6992675.

152: Donadio D, Navarro M, Izarn P, Clot J, Emberger JM. [Angioimmunoblastic lymphadenopathy. Remission obtained with prednimustine after failure of corticosteroid therapy and cyclophosphamide]. Nouv Presse Med. 1980 Jan 12;9(3):188-9. French. PubMed PMID: 7355106.

153: Rørth M, Løber J, Dombernowsky P, Krusenstjerna-Hofstrom D, Mattsson W, Mouridsen HT. A phase III study of prednimustine (LEO 1031) in advanced breast cancer. A preliminary report. Eur J Cancer. 1980;Suppl 1:137-40. PubMed PMID: 7032923.

154: Pedersen-Bjergaard J, Hansen MM, Geisler CH, Nissen NI. Clinical trial of prednimustine, Leo-1031 (NSC-134087), in patients with non-Hodgkin lymphomata and chronic lymphocytic leukaemia previously treated with steroids and alkylating agents. Acta Med Scand. 1980;207(3):215-20. PubMed PMID: 6989170.

155: Beckley S, Wajsman Z, Slack N, Mittelman A, Murphy GP. The chemotherapy of prostatic carcinoma. Scand J Urol Nephrol Suppl. 1980;55:151-62. PubMed PMID: 6938019.

156: Könyves I. Hormone cytostatic agents. Scand J Urol Nephrol Suppl. 1980;55:127-32. PubMed PMID: 6938015.

157: Jensen HS, Hansen HH, Dombernowsky P. Phase II trial of prednimustine (NSC-134087) in the treatment of small-cell anaplastic carcinoma of the lung. Cancer Chemother Pharmacol. 1980;4(4):259-61. PubMed PMID: 6254684.

158: Juul K, Sørensen P, Pedersen-Bjergaard J, Jensen MK. Phase II trial of Prednimustine. Leo-1031 (NSC-134087) in acute non-lymphocytic leukemia. Scand J Haematol. 1979 Nov;23(5):388-92. PubMed PMID: 396664.

159: Newell DR, Hart LI, Harrap KR. Estimation of chlorambucil, phenyl acetic mustard and prednimustine in human plasma by high-performance liquid chromatography. J Chromatogr. 1979 Sep 11;164(1):114-9. PubMed PMID: 541393.

160: Slack NH, Murphy GP. Prednimustine for prostate cancer therapy. Compr Ther. 1979 Sep;5(9):54-7. PubMed PMID: 487742.

161: Murphy GP, Gibbons RP, Johnson DE, Prout GR, Schmidt JD, Soloway MS, Loening SA, Chu TM, Gaeta JF, Saroff J, Wajsman Z, Slack N, Scott WW. The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation. J Urol. 1979 Jun;121(6):763-5. PubMed PMID: 458947.

162: Johnsson JE, Tropé C, Mattsson W, Grundsell H, Aspegren K, Könyves I. Phase II study of Leo 1031 (prednimustine) in advanced ovarian carcinoma. Cancer Treat Rep. 1979 Mar;63(3):421-4. PubMed PMID: 371798.

163: Brandt L, Könyves I. Prednimustine in adult acute myeloid leukaemia. Cancer Chemother Pharmacol. 1979;2(2):133-6. PubMed PMID: 394873.

164: Molin L, Thomsen K, Volden G, Bergqvist-Karlsson A, Hellbe L. Prednimustine in mycosis fungoides: a report from the Scandinavian mycosis fungoides study group. Acta Derm Venereol. 1979;59(1):87-8. PubMed PMID: 84481.

165: Lambert B, Ringborg U, Harper E, Lindblad A. Sister chromatid exchanges in lymphocyte cultures of patients receiving chemotherapy for malignant disorders. Cancer Treat Rep. 1978 Oct;62(10):1413-9. PubMed PMID: 709547.

166: Fredholm B, Gunnarsson K, Jensen G, Müntzing J. Mammary tumour inhibition and subacute toxicity in rats of prednimustine and of its molecular components chlorambucil and prednisolone. Acta Pharmacol Toxicol (Copenh). 1978 Mar;42(3):159-63. PubMed PMID: 580343.

167: Catane R, Kaufman JH, Madajewicz S, Mittelman A, Murphy GP. Prednimustine therapy for advanced prostatic cancer. Br J Urol. 1978 Feb;50(1):29-32. PubMed PMID: 630199.

168: Murphy GP, Gibbons RP, Johnson DE, Prout GR, Schmidt JD, Soloway MS, Loening SA, Chu TM, Gaeta JF, Saroff J, Wajsman Z, Slack N, Scott WW. The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation. Trans Am Assoc Genitourin Surg. 1978;70:69-71. PubMed PMID: 753026.

169: Håkansson L, Könyves I, Lindberg LG, Möller T. Continuous treatment of non-Hodgkin's malignant lymphoma with prednimustine (Leo 1031). Oncology. 1978;35(3):103-6. PubMed PMID: 673314.

170: Kirdani RY, Murphy GP, Sandberg AA. Some metabolic aspects of a nitrogen mustard of prednisolone. Oncology. 1978;35(2):47-53. PubMed PMID: 652263.

171: Mattsson W, von Eyben F, Turesson I, Wählby S. Prednimustine (NSC-134087, Leo 1031) treatment of lymphocytic and lymphocytic-histiocytic lymphomas. Cancer. 1978 Jan;41(1):112-6. PubMed PMID: 342081.

172: Bringel C, Jakobsson PA, Könyves I, Nordenskjöld B, Strander H, Wiman LG. Combined treatment of bronchogenic carcinoma with radiotherapy and cytotoxic drugs--a pilot study using prednimustine and chloroethylcyclohexylnitrosurea (CCNU). Scand J Respir Dis Suppl. 1978;102:223-5. PubMed PMID: 278211.

173: Harrap KR, Riches PG, Gilby ED, Sellwood SM, Wilkinson R, Konyves I. Studies on the toxicity and antitumour activity of prednimustine, a prednisolone ester of chlorambucil. Eur J Cancer. 1977 Aug;13(8):873-81. PubMed PMID: 908348.

174: A phase II clinical trial of prednimustine. Clinical screening cooperative group of E.O.R.T.C. Biomedicine. 1977 Jun;27(4):158-61. PubMed PMID: 329910.

175: Brandt L, Könyves I. [Prednimustine in treatment of acute leukemia in elderly patients]. Lakartidningen. 1977 Apr 13;74(15):1490-3. Swedish. PubMed PMID: 321896.

176: Brandt L, Könyves I. Therapeutic effect of prednimustine (LEO 1031) in various types of leukaemia. Eur J Cancer. 1977 Apr-May;13(4-5):393-8. PubMed PMID: 326550.

177: Mittelman A, Catane R, Murphy GP. New steroidal alkylating agents in advanced stage D carcinoma of the prostate. Cancer Treat Rep. 1977 Mar-Apr;61(2):307-10. PubMed PMID: 872134.

178: Catane R, Kaufman J, Mittelman A, Murphy GP. Combined therapy of advanced prostatic carcinoma with estramustine and prednimustine. J Urol. 1977 Mar;117(3):332-5. PubMed PMID: 839597.

179: Jakhammer T, Olsson A, Svensson L. Mass fragmentographic determination of prednimustine and chlorambucil in plasma. Acta Pharm Suec. 1977;14(5-6):485-96. PubMed PMID: 596165.

180: Lutz D, Böhnel J. [Effect of Prednimustine (Leo 1031) in chronic lymphatic leukemia]. Osterr Z Onkol. 1977;3(5-6):155-9. German. PubMed PMID: 323777.

181: Catane H, Catane R, Takita H, Kaufman JH, Mittelman A, Murphy GP. Preliminary clinical study of prednimustine in lung cancer. J Med. 1977;8(2):115-21. PubMed PMID: 268397.

182: Könyves I, Nordenskjöld B, Forshell GP, de Schryver A, Westerberg-Larsson H. Preliminary clinical and absorption studies with prednimustine in patients with mammary carcinoma. Eur J Cancer. 1975 Dec;11(12):841-4. PubMed PMID: 767114.